Search

Displaying results 3651 - 3660 of 8575 in total
  1. Drug

    Diphemanil

    go.drugbank.com/drugs/DB13720
    ApprovedVet approvedWithdrawn

  2. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

  3. Drug

    Setidegrasib

    go.drugbank.com/drugs/DB21670
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Setidegrasib is a Ras protein inhibitor. Setidegrasib has a monoisotopic molecular weight of 1116.48 Da.

  4. Drug

    Arzoxifene

    go.drugbank.com/drugs/DB06249
    ApprovedWithdrawn

  5. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).

  6. Drug

    Tolevamer

    go.drugbank.com/drugs/DB01344
    Approved

    It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines.

  7. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  8. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic respon...

  9. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues. … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.

  10. Drug

    Gadolinium

    go.drugbank.com/drugs/DB12091
    ApprovedInvestigationalWithdrawn

    Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.